Transplant of hematopoietic stem cells in childhood

Where we are and where we are going

Franco Locatelli, Giuseppe Roberto Burgio

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Over the past decade, relevant improvements and refinements have significantly changed the indications, technique and results obtained with allogeneic transplantation of hematopoietic stem cells (HSC) in childhood. In this review the most important innovations that have characterized the practice of HSC transplantation in childhood during this decade will be discussed. We will analyze the clinical and biological advantages or disadvantages which characterize most typically HSC transplantation procedure in terms of the source of these cells (bone marrow, peripheral blood, placental blood). A fundamental turning point in the history of allogeneic transplantation of HSC is represented by the use of placental blood, which was first employed in 1988. Autologous, peripheral blood progenitor cells are increasingly being used as a source of HSC following high-dose therapy for malignant disease, because of the ease of collection and the markedly faster kinetics of engraftment in comparison with bone marrow. In particular, over the past decade, due to the much faster recovery of all hematopoietic lineages in comparison with bone marrow and due to the short duration of antibiotic therapy and hospitalization, also in pediatric patients, autotransfusion of circulating hematopoietic progenitors is rapidly replacing autologous bone marrow transplantation after high-dose chemotherapy for lymphomas and solid tumors. On the contrary, due to concerns in pediatric patients related to the use of hematopoietic growth factors in a healthy donor, allograft of peripheral blood progenitor cells is not routinely used. Since indications for allogeneic HSC transplantation that had already been well established in the recent past have been complemented by others and a relevant number of disorders are no longer considered to be eligible for allograft, the evolution in the indications for allogeneic transplant of HSC In childhood will be discussed. Likewise, biotechnological, social and organizational refinements which have allowed the greatest advances of allogeneic HSC transplantation in this decade will be analyzed, as well as some still open bioethical question regarding this procedure.

Original languageEnglish
Pages (from-to)550-563
Number of pages14
JournalHaematologica
Volume83
Issue number6
Publication statusPublished - Jun 1998

Fingerprint

Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells
Transplants
Homologous Transplantation
Allografts
Blood Cells
Stem Cells
Bone Marrow
Pediatrics
Autologous Blood Transfusions
Autologous Transplantation
Bone Marrow Transplantation
Bone Marrow Cells
Lymphoma
Intercellular Signaling Peptides and Proteins
Hospitalization
History
Tissue Donors
Anti-Bacterial Agents
Drug Therapy

Keywords

  • Bioethics and transplantation
  • Bone marrow transplantation
  • Hematopoietic stem cell transplantation
  • Peripheral blood transplantation
  • Placental blood transplantation
  • Transplant of hematological disorders in childhood

ASJC Scopus subject areas

  • Hematology

Cite this

Transplant of hematopoietic stem cells in childhood : Where we are and where we are going. / Locatelli, Franco; Burgio, Giuseppe Roberto.

In: Haematologica, Vol. 83, No. 6, 06.1998, p. 550-563.

Research output: Contribution to journalArticle

@article{2c723dd4bcfb48ae9a1fec24fa68c798,
title = "Transplant of hematopoietic stem cells in childhood: Where we are and where we are going",
abstract = "Over the past decade, relevant improvements and refinements have significantly changed the indications, technique and results obtained with allogeneic transplantation of hematopoietic stem cells (HSC) in childhood. In this review the most important innovations that have characterized the practice of HSC transplantation in childhood during this decade will be discussed. We will analyze the clinical and biological advantages or disadvantages which characterize most typically HSC transplantation procedure in terms of the source of these cells (bone marrow, peripheral blood, placental blood). A fundamental turning point in the history of allogeneic transplantation of HSC is represented by the use of placental blood, which was first employed in 1988. Autologous, peripheral blood progenitor cells are increasingly being used as a source of HSC following high-dose therapy for malignant disease, because of the ease of collection and the markedly faster kinetics of engraftment in comparison with bone marrow. In particular, over the past decade, due to the much faster recovery of all hematopoietic lineages in comparison with bone marrow and due to the short duration of antibiotic therapy and hospitalization, also in pediatric patients, autotransfusion of circulating hematopoietic progenitors is rapidly replacing autologous bone marrow transplantation after high-dose chemotherapy for lymphomas and solid tumors. On the contrary, due to concerns in pediatric patients related to the use of hematopoietic growth factors in a healthy donor, allograft of peripheral blood progenitor cells is not routinely used. Since indications for allogeneic HSC transplantation that had already been well established in the recent past have been complemented by others and a relevant number of disorders are no longer considered to be eligible for allograft, the evolution in the indications for allogeneic transplant of HSC In childhood will be discussed. Likewise, biotechnological, social and organizational refinements which have allowed the greatest advances of allogeneic HSC transplantation in this decade will be analyzed, as well as some still open bioethical question regarding this procedure.",
keywords = "Bioethics and transplantation, Bone marrow transplantation, Hematopoietic stem cell transplantation, Peripheral blood transplantation, Placental blood transplantation, Transplant of hematological disorders in childhood",
author = "Franco Locatelli and Burgio, {Giuseppe Roberto}",
year = "1998",
month = "6",
language = "English",
volume = "83",
pages = "550--563",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Transplant of hematopoietic stem cells in childhood

T2 - Where we are and where we are going

AU - Locatelli, Franco

AU - Burgio, Giuseppe Roberto

PY - 1998/6

Y1 - 1998/6

N2 - Over the past decade, relevant improvements and refinements have significantly changed the indications, technique and results obtained with allogeneic transplantation of hematopoietic stem cells (HSC) in childhood. In this review the most important innovations that have characterized the practice of HSC transplantation in childhood during this decade will be discussed. We will analyze the clinical and biological advantages or disadvantages which characterize most typically HSC transplantation procedure in terms of the source of these cells (bone marrow, peripheral blood, placental blood). A fundamental turning point in the history of allogeneic transplantation of HSC is represented by the use of placental blood, which was first employed in 1988. Autologous, peripheral blood progenitor cells are increasingly being used as a source of HSC following high-dose therapy for malignant disease, because of the ease of collection and the markedly faster kinetics of engraftment in comparison with bone marrow. In particular, over the past decade, due to the much faster recovery of all hematopoietic lineages in comparison with bone marrow and due to the short duration of antibiotic therapy and hospitalization, also in pediatric patients, autotransfusion of circulating hematopoietic progenitors is rapidly replacing autologous bone marrow transplantation after high-dose chemotherapy for lymphomas and solid tumors. On the contrary, due to concerns in pediatric patients related to the use of hematopoietic growth factors in a healthy donor, allograft of peripheral blood progenitor cells is not routinely used. Since indications for allogeneic HSC transplantation that had already been well established in the recent past have been complemented by others and a relevant number of disorders are no longer considered to be eligible for allograft, the evolution in the indications for allogeneic transplant of HSC In childhood will be discussed. Likewise, biotechnological, social and organizational refinements which have allowed the greatest advances of allogeneic HSC transplantation in this decade will be analyzed, as well as some still open bioethical question regarding this procedure.

AB - Over the past decade, relevant improvements and refinements have significantly changed the indications, technique and results obtained with allogeneic transplantation of hematopoietic stem cells (HSC) in childhood. In this review the most important innovations that have characterized the practice of HSC transplantation in childhood during this decade will be discussed. We will analyze the clinical and biological advantages or disadvantages which characterize most typically HSC transplantation procedure in terms of the source of these cells (bone marrow, peripheral blood, placental blood). A fundamental turning point in the history of allogeneic transplantation of HSC is represented by the use of placental blood, which was first employed in 1988. Autologous, peripheral blood progenitor cells are increasingly being used as a source of HSC following high-dose therapy for malignant disease, because of the ease of collection and the markedly faster kinetics of engraftment in comparison with bone marrow. In particular, over the past decade, due to the much faster recovery of all hematopoietic lineages in comparison with bone marrow and due to the short duration of antibiotic therapy and hospitalization, also in pediatric patients, autotransfusion of circulating hematopoietic progenitors is rapidly replacing autologous bone marrow transplantation after high-dose chemotherapy for lymphomas and solid tumors. On the contrary, due to concerns in pediatric patients related to the use of hematopoietic growth factors in a healthy donor, allograft of peripheral blood progenitor cells is not routinely used. Since indications for allogeneic HSC transplantation that had already been well established in the recent past have been complemented by others and a relevant number of disorders are no longer considered to be eligible for allograft, the evolution in the indications for allogeneic transplant of HSC In childhood will be discussed. Likewise, biotechnological, social and organizational refinements which have allowed the greatest advances of allogeneic HSC transplantation in this decade will be analyzed, as well as some still open bioethical question regarding this procedure.

KW - Bioethics and transplantation

KW - Bone marrow transplantation

KW - Hematopoietic stem cell transplantation

KW - Peripheral blood transplantation

KW - Placental blood transplantation

KW - Transplant of hematological disorders in childhood

UR - http://www.scopus.com/inward/record.url?scp=0031820549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031820549&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 550

EP - 563

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -